Nova Immunotherapeutics Limited

The company has conducted or sponsored at least two Phase I clinical trials: * One trial is a randomized, double-masked, placebo-controlled Phase I study evaluating an MAS‑1-adjuvanted antigen-specific immunotherapy for the prevention/treatment of Type I Diabetes. The goal is to assess safety and potential immune tolerance induction. * Another trial evaluated the safety, tolerance, and immunogenicity of a MAS‑1-adjuvanted seasonal inactivated influenza vaccine with hemagglutinin dose escalation compared to standard non-adjuvanted vaccines in healthy adults/elderly. Status unknown; no published efficacy results found.[4]